**CURRICULUM VITAE**

**PERSONAL DATA**

Frederik Debruyne

Honsdonkstraat 55

3120 Tremelo

Belgium

Mail [freddebruyne@yahoo.com](mailto:freddebruyne@yahoo.com)

Mobile phone +32 (0)479/608157

Date of birth & place October 4th 1976, Torhout Belgium

Marital status married

Nationality Belgian

Profile on linked in

# **EDUCATION**

**Secundary school** Sint-Jozefsinstituut – Torhout

1988-1994: graduation in maths (8 h/week) – science

**Higher education** Katholieke Universiteit Leuven – Leuven, Belgium

1994-1999: dentistry

1999-2004: medicine

1999-2000: 2de & 3e bachelor

2000-2001: 1th master

2001-2002: 2nd master

2002-2003: · 3nd master

Training in surgery in CHU Claude-Bernard-Bichat in Paris, France

2003-2004: 4th master

Training in neurology in the university hospital Leuven, Belgium.

Subject of final paper: Intravenous VPA as a second-line anti-epileptic drug in the treatment of status epilepticus (open label study). The results of this study were presented on the ILAE-congress in Vienna june 2004.

Optional courses during medicine:

- medical French

- medical English

- anesthaesiology

- tropical medicine

2004 -2009: training in neurology

2004-2005: 1st year in neurology in OLV-hospital in Aalst, Belgium

(dr. Caecebeke – dr.Van Orshoven)

2005-2006: 2nd year in neurology in UZ Leuven (prof. dr. Robberecht)

2006-2007: 3nd year in neurology in UZ Leuven (prof. dr. Robberecht)

2007-2008: 4th year in neurology in UZ Leuven (prof. dr. Robberecht)

with a 3 months training in neurosurgery

01-08-2008: 5th year in neurology in UZ Leuven (prof. dr. Robberecht)

with a 3 months training in pediatric neurology

2009 - present: general neurologist in the GZA ziekenhuizen Antwerp, Belgium ([www.gza.be](http://www.gza.be)), with special interest in MS, headache and infiltrations with botulinum toxin.

Also working in a polyclinic ([www.dlo.be](http://www.dlo.be)) , and in a nursing home (WZC damiaan – Tremelo) and private practice ‘de neuropraktijk’ ([www.neuropraktijk.be](http://www.neuropraktijk.be)). Previously temporary working in ZNA hospitals and (MS-) rehabilition center ‘de Mick’.

Infiltrating botulinum toxin since 2013 (course AAN) for migraine, dystonia, spasticity and hemifacial spasm.

Member of the Belgische Studiegroep voor multiple sclerose ([www.bsgms.org](http://www.bsgms.org)) .

MS expert according to the belgian law since 2012. Organisation of a multidisciplinary MS consultation in collaboration with National MS Center and the MS liga. Also set up of Modis program in GZA for psychological care for people with MS.

Neurostatus/EDSS qualification level C december 12th 2011 and june 2022

Member of the belgian headache society, VVN, AAN, EAN and INA

Certificate ‘Good Clinical Practice’ 2019 and 2022

Organizer and owner of the url domain neurologie-antwerpen.be ([www.neurologie-antwerpen.be](http://www.neurologie-antwerpen.be))

Supervisor for the trainees in neurology (UGent) in GZA since 2019.

UPDRS-certificate since 2009

Contributor to WOMS, a magazine of the MS liga Vlaanderen

Publications:

Prospective, open-label study of intravenous VPA as a second-line anti-epileptic drug in the treatment of status epilepticus. Abstract in *Epilepsia Vol 45, Suppl. 3, 2004; 82.*

Tijd voor een herevaluatie van het beleid bij angionegatieve SAB? *Tijdschrift voor neurologie en neurochirurgie*, vol 109, nr2, 2008; 88)

Neurodegenerative parkinsonism and progressive external ophthalmoplegia with a Twinkle mutation. *Movement Disorders* Vol 24 (2) 2009; p 308

Paroxysmal nonkinesigenic dyskinesias due to recurrent hypoglycaemia caused by an insulinoma. *Movement Disorders* Vol 24 (3) 2009; p 460

Migraine presenting as chronic facial pain. *Acta Neurologica Belgica* Vol 109/3 2009, N°3; p 235 - 237.

Acute neuropathie in het kader van het churg-strausssyndroom. *Tijdschr Neurol en Neurochir* 2012;113:245-50)

Metastasering van het diffuus grootcellig B-cel non-hodgkinlymfoom naar het centrale zenuwstelsel. *Tijdschrift voor neurologie en neurochirurgie* vol 115, nr2, 2014, p196

The BELTRIMS registry: real-world safety and efficacy of DMTs in Belgium. Collaborator; *Abstract Ectrims, Oct 10, 2018; 229466*

Paraneoplastic tumefactive demyelination in a 47-year-old man with underlying seminoma. *MS and related disorders*. Vol 42 July 2020

Evaluation of a mandatory drug holiday during treatment with monoclonal antibodies targeting the cgrp pathway: a patient survey.

Collaborator; *poster European Headache Federation congress Vienna December 2022*

Incidentally Detected Diffuse Intracerebral Calcifications. Neurology India, in review

PI of the remodel-1 study site GZA (a randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib 100 mg bid versus teriflunomide 14 mg qd in participants with relapsing remitting multiple sclerosis, followed by extended treatment with open-label remibrutinib. Jan 2023

Sub-PI of the study BHV3000-406 (A Phase 4, Randomized, Double-Blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use)

and 407 (A Phase 4, Randomized, Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequate Response to Oral Preventive Medications). June 2023

## GENERAL KNOWLEDGE

Mobility Driving Licence B (belgian)

Dactylography Excellent (dutch, french, english and german)

Working attitude Great flexibility

IT fluently (Windows – Office)

# **LANGUAGES**

Dutch native speaker

French/English fluently

Italian notions

Polish threshold 4 – B1

German notions

Russian notions